Results 261 to 270 of about 252,541 (298)
Some of the next articles are maybe not open access.

Structure of the genes encoding the CD19 antigen of human and mouse B lymphocytes

Immunogenetics, 1992
CD19 is a B lymphocyte cell-surface marker that is expressed early during pre-B-cell differentiation with expression persisting until terminal differentiation into plasma cells. CD19 is a member of the Ig gene superfamily with two extracellular Ig-like domains separated by a non-Ig-like domain, and with an extensive approximately 240 amino acid ...
L J, Zhou   +3 more
openaire   +2 more sources

Point of care CD19 chimeric antigen receptor (CAR) T-cells for relapsed/refractory acute myeloid leukemia (AML) with aberrant CD19 antigen expression

Current Research in Translational Medicine
Relapsed/refractory (r/r) acute myeloid leukemia (AML) is associated with poor prognosis. CD19 is a B-cell marker, is aberrantly expressed in AML, mostly with t(8; 21)(q22; q22.1). Here we report the results of a phase 2 study giving point of care produced CD19 CAR T- cells for r/r AML with aberrant expression of CD19 (NCT04257175).
Ivetta Danylesko   +9 more
openaire   +2 more sources

Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy

Expert Opinion on Biological Therapy, 2020
Cameron J Turtle, Cassie K Chou
exaly  

Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a review

Leukemia and Lymphoma, 2023
Renato Bassan   +2 more
exaly  

Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma

Annals of Oncology, 2018
Mariano Provencio   +2 more
exaly  

Home - About - Disclaimer - Privacy